MAPK1
Reaktivität: Human
WB, ELISA, IHC, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Probenmenge
20 μL
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
Aqueous buffered solution containing BSA and ≤0.09 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Informationen zur Lagerung
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The antibody was conjugated to Alexa Fluor® 647 under optimum conditions, and unreacted Alexa Fluor® 647 was removed.
Sivaraman, Wang, Nuovo, Malbon: "Hyperexpression of mitogen-activated protein kinase in human breast cancer." in: The Journal of clinical investigation, Vol. 99, Issue 7, pp. 1478-83, (1997) (PubMed).
Target
ERK2 (MAPK1)
(Mitogen-Activated Protein Kinase 1 (MAPK1))
The members of the Mitogen-Activated Protein Kinase (MAPK) family are components of a key signal transduction cascade that links events at the cell surface to responses in the nucleus. The signaling cascade is found in species as varied as yeast and humans, with many of the proteins being well conserved. In mammals the most widely studied members of the cascade are the Extracellular signal-Regulated Kinases, ERK1 (p44 MAPK) and ERK2 (p42 MAPK). ERK1 and ERK2 share 85% homology and are activated by extracellular signals such as growth factors, hormones, and phorbol esters. Activation occurs through a series of phosphorylations by kinases activating other kinases and eventually leading to phosphorylation of the ERKs. Growth factor stimulation leads to activation of Ras and Raf, leading to phosphorylation of MEK1 (MAPK/ERK kinase) which, in turn, activates the ERKs via dual phosphorylation. Once activated, the ERKs phosphorylate other cytoplasmic signalling molecules (protein kinases and phosphatases), cell-surface receptors, microtubule-associated proteins, and transcription factors in the nucleus. Thus, the active ERK has myriad downstream effectors that implicate it in the control of cell proliferation and differentiation, as well as regulation of the cytoskeleton. Furthermore, studies have shown that elevated ERK activity is associated with some cancers. The G263-7 recognizes ERK2. It does not cross-react with ERK1. Clone G263-7 was originally characterized in human (A431) and mouse (NIH/3T3) cells.A human ERK2 synthetic peptide was used as immunogen.